Profiling the HCV immune response in patients with chronic liver diseases and hepatocellular carcinoma by peptide microarray analysis
| Autor: | Luigi Buonaguro, Anna Lucia Tornesello, Franco M. Buonaguro, Tobias Knaute, Maria Lina Tornesello, Angelo Salomone Megna, Francesca Pezzuto, Francesco Izzo, Pavlo Holenya, Ulf Reimer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Carcinoma
Hepatocellular Cirrhosis medicine.medical_treatment Hepatitis C virus Lymphoproliferative disorders Hepacivirus medicine.disease_cause Biochemistry Immune system Drug Discovery medicine Humans Pharmacology biology business.industry Liver Neoplasms Organic Chemistry Immunity virus diseases Immunotherapy Microarray Analysis medicine.disease Hepatitis C digestive system diseases Cryoglobulinemia Hepatocellular carcinoma Immunology Disease Progression biology.protein Molecular Medicine Antibodies Hepatitis C virus (HCV) Hepatocellular carcinoma (HCC) Mixed cryoglobulinemia (MC) Peptide biomarker Peptides microarray Peptide microarray Antibody Peptides business |
| DOI: | 10.5281/zenodo.5148350 |
| Popis: | Background: Chronic infection with hepatitis C virus (HCV) is among the major causes of hepatic fibrosis, cirrhosis, as well as hepatocellular carcinoma (HCC), and it is associated with a significant risk of developing lymphoproliferative disorders. The rate of clinical disease progression is variable depending on multiple host and viral factors, including immune response. Methods: To perform a comprehensive epitope mapping of anti-HCV antibodies in patients suffering from HCV-related liver or lymphoproliferative diseases, we analyzed clinical samples on a peptide microarray platform made of 5952 overlapping 15-mer synthetic peptides derived from the whole HCV proteome. We evaluated the antibody profile of 71 HCV-positive patients diagnosed with HCC, mixed cryoglobulinemia (MC), and HCV chronic infection. Antibody reactivity against virus peptides was detected in all HCV-positive patients. Importantly, the signal amplitude varied significantly within and between diverse patient groups. Results: Antibody reactivity against C peptides were found generally low in HCV chronically infected asymptomatic subjects and increasingly high in HCC and MC patients. Moreover, we found a statistically significant higher IgG response in HCC and MC patients against specific domains of HCV C, E2, NS3, NS4A, NS4B, NS5A, and p7 compared to HCV-positive subjects. Conclusion: In conclusion, our data suggest that immune response against specific HCV protein domains may represent useful biomarkers of disease progression among HCV-positive patients and suggest that peptide microarrays are good tools for the screening of immunotherapy targets in preclinical HCV research. PMID: 34736375 DOI: 10.2174/0929867328666211104093718 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|